Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized trial of APO-EPO epoetin alfa in anemia of CKD stage 5D
2011-005057-31Phase 3Completed
- Sponsor
- Apotex Inc.
- Start
- Aug 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of epoetin alfa in anaemia and chronic kidney disease (CKD) (2 arms), sponsored by Apotex Inc. Primary endpoint: Mean weekly epoetin dose per kg to maintain hemoglobin 10.0–11.0 g/dL (correction phase). Started Aug 2012; status: completed.
02
Drugs
epoetin alfa
03
Conditions
anaemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on 2011-005057-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005057-31.